Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action

Eslicarbazepine acetate (ESL) is a once daily antiepileptic drug (AED) approved by the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and Health Canada as an adjunctive therapy in adults with partial-onset seizures (POS). In humans and in relevant animal laboratory species,...

Descripción completa

Detalles Bibliográficos
Autores principales: Soares-da-Silva, Patrício, Pires, Nuno, Bonifácio, Maria João, Loureiro, Ana I, Palma, Nuno, Wright, Lyndon C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448990/
https://www.ncbi.nlm.nih.gov/pubmed/26038700
http://dx.doi.org/10.1002/prp2.124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448990/
https://www.ncbi.nlm.nih.gov/pubmed/26038700
http://dx.doi.org/10.1002/prp2.124

Ejemplares similares